If market reach or potential target population, increases 10 fold, from 4 mm to 36 mm, what would this be worth for a bigger pharma with deep pockets which can easily market.
If AdComm gives the thumbs up for ANCHOR, AMRN will open up 100% and then trade up an additional 20%+ minimum that 1st trading day. Expect stock price to rise all the way into FDA approval as buyout/partnership scenarios will come into play
Basically if REDUCE-IT is successful and ANCHOR is approved this stock should be trading at least a 10 billion market capitalization. Given the safety profile and likelihood of benefit of EPA supplementation based off of already completed studies, this drug SHOULD be approved for ANCHOR. The question is if the FDA is going to do what's right for the general public. I hope the people there at the meeting pose very well-articulated and poignant questions that really drive home this point to the panel members.
I really don't like to predict outcomes as they're usually wrong. It is mind boggling if you consider what JZ said about a potential population that could reach 70 million Americans alone. This includes type 2 diabetics, Alzheimer's, CHD etc
The journey begins anew on Wednesday. Oct. 16th.
Doing a quick math calculation I come up with $26 billion market. Here's how I got there.
36 million potential x 50% penetration x $1800 per year per prescription equals 18 million scripts x $1800 = $32.4 billion revs (annually) x profit margin (80%) = $26 billion net per year.